Adjuvant radiotherapy of regional lymph nodes in breast cancer - a meta-analysis of randomized trials

Radiation Oncology

Table 2 Late toxicity in breast cancer trials on regional radiotherapy

Trial late toxicity	MA.20[16]			EORTC[17]			French[15]
Trial late toxicity	MS-IM-	IM-IM+	p	MS-IM-	IM-IM+	p	MS+	IM-IM+	p
Lung
Grade 2	0.2%	1.3	0.01	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
Grade >2	0%	0%	n.a.	n.s.
Any grade n.a	n.a.	n.a.	n.a.	1.3%	4.3%	<0.0001	n.a.	n.a.	n.a.
Lymphedema
Grade 2	3.7%	6.8%	0.004	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
Grade >2	0.4%	0.4%	n.s.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
Any grade (arm)	n.a.	n.a.	n.a.	3.6%	3.8%	n.s.	n.a.	n.a.	n.a.
Cardiac
Any grade	n.a.	n.a.	n.a.	1.4%	1.6%	n.s.	1.7%	2.2%	n.s
Total late
Any grade	n.a.	n.a.	n.a.	21.8%	25.5%	0.006	n.a.	n.a.	n.a.
Grade >2	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	2.3%	3.1%	n.s.

Late toxicitiy.
n.a. = not available; n.s. = not significant; MS-IM-: no radiotherapy of the medial supraclavicular and internal mammary lymph nodes; MS-IM+: radiotherapy of the medial supraclavicular and internal mammary lymph nodes; MS+: radiotherapy of the medial supraclavicular lymph nodes.

ISSN: 1748-717X